ユニキュア社、ハンチントン病治療薬AMT-130遺伝子治療の第I/II相臨床試験の最新情報を発表

~ Patients treated with AMT-130 continue to show evidence of preserved neurological function with potential dose-dependent clinical benefits relative to an inclusion criteria-matched natural history of the disease ~ ~ Mean CSF NfL continue to demonstrate favorable trends with low-dose patients 続きを読む...

jaJapanese